LAMB1 Is Related to the T Stage and Indicates Poor Prognosis in Gastric Cancer

Tao Ran, MD1*, Zhiji Chen, MD1, LiWen Zhao, MD1, Wei Ran2, JinYu Fan, MD1, SiYa Hong, MD1, and ZhaoXia Yang, PhD, MD1

Abstract

Background and Objective: Gastric cancer (GC) is a common tumor malignancy with high incidence and poor prognosis. Laminin is an indispensable component of basement membrane and extracellular matrix, which is responsible for bridging the internal and external environment of cells and transmitting signals. This study mainly explored the association of the LAMB1 expression with clinicopathological characteristics and prognosis in gastric cancer. Methods: The expression data and clinical information of gastric cancer patients were downloaded from the Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG). And we analyzed the relationship between LAMB1 expression and clinical characteristics through R. CIBERSORTx was used to calculate the absolute score of immune cells in gastric tumor tissues. Then COX proportional hazard models and Kaplan-Meier curves were performed to evaluate the role of LAMB1 and its influence on prognosis in gastric cancer patients. Finally, GO and KEGG analysis were applied for LAMB1-related genes in gastric cancer, and PPI network was constructed in Cytoscape software. Results: In the TCGA cohort, patients with gastric cancer frequently generated LAMB1 gene copy number variation, but had little effect on mRNA expression. Both in the TCGA and ACRG cohorts, the mRNA expression of LAMB1 in gastric cancer tissues was higher than in normal tissues. All patients were divided into high expression group and low expression group according to the median expression level of LAMB1. The elevated expression group obviously had more advanced cases and higher infiltration levels of M2 macrophages. COX proportional hazard models and Kaplan-Meier curves revealed that patients with enhanced expression of LAMB1 have a worse prognosis. GO/KEGG analysis showed that LAMB1-related genes were enriched in PI3K-Akt signaling pathway, focal adhesion, ECM-receptor interaction, etc. Conclusions: The high expression of LAMB1 in gastric cancer is related to the poor prognosis of patients, and it may be related to microenvironmental changes in tumors.

Keywords

the β1 subunit of laminin, LAMB1, gastric cancer, GC, prognosis, tumor microenvironment, TME, CIBERSORTx, survival, therapeutic target, tumor-infiltrating immune cells, TICs

Received: January 25, 2021; Revised: January 25, 2021; Accepted: February 09, 2021.

Introduction

According to the report from the World Health Organization (WHO: http://www.who.int/cancer/en/), Gastric cancer (GC) is one of the most common cancers worldwide.1 The incidence of gastric cancer (GC) has been declining in the past few decades worldwide. However, GC is still the fifth most frequently diagnosed cancer and the third leading cause of cancer-related death.2 Despite tremendous advances in surgery, radiotherapy, chemotherapy and targeted molecular therapy, the overall effectiveness of treatment is low, with a poor median overall survival (OS) which is shorter than 1 year. Many biomarkers had been developed for the prognosis prediction of gastric cancer.
patients with advanced GC and the early diagnosis of gastric cancer, but few biomarkers can be used in clinical practice.\textsuperscript{3,5} Moreover, as multiple clinical trials of targeted drugs for gastric cancer have failed, there is an urgent need to explore more sensitive and specific GC-related biomarkers as diagnostic and therapeutic targets.

Laminin is a large molecular weight glycoprotein assembled by 3 disulfide-bonded polypeptides ($\alpha$, $\beta$ and $\gamma$ chains).\textsuperscript{6,7} It is an indispensable component for cells to bridge the internal and external environments of cells and carry out signal transmission. It is also a basement membrane and an essential component of the extracellular matrix. Including 5 alpha chains (LAMA1, LAMA2, LAMA3, LAMA4 and LAMA5), 4 beta chains (LAMB1, LAMB2, LAMB3 and LAMB4), and 3 gamma chains (LAMC1, LAMC2 and LAMC3), the human genome encodes for 12 different laminin chains varying in expression and distribution within the tissues. The $\beta$1 subunit (LAMB1) is ubiquitously expressed in skin, kidneys, lungs, intestine, bladder and stomach. And in addition to their role in maintaining structural integrity of tissues, the laminin-binding $\beta$1 also involved in the function of bidirectional signaling. Current studies have shown that LAMB1 plays an important role in a variety of tumors, such as prostate cancer,\textsuperscript{8} hepatocellular carcinoma,\textsuperscript{9} breast cancer and\textsuperscript{11} glioblastoma multiforme. However, there is limited systematic research investigating the associations between LAMB1 mRNA expression and patients’ with gastric cancer clinicopathological characteristics and prognosis. Therefore, based on The Cancer Genome Atlas database (TCGA) and Asian Cancer Research Group (ACRG) dataset, this study retrospectively investigated the transcriptome and genome of LAMB1 in gastric cancer and its impact on the prognosis of gastric cancer. Furthermore, the genomic changes and functional networks in GC related to LAMB1 had been analyzed.

Materials and Methods

Data Resource and Description

Demographic information and clinical data, as well as expression data (genomic data was included in TCGA cohort) of gastric cancer was selected from the Asian Cancer Research Group (ACRG) study and The Cancer Genome Atlas (TCGA) dataset, The ACRG cohort (GSE66229) containing gastric cancer expression data of tumor and non-tumor samples were obtained from the National Center for Biotechnology Information’s (NCBI) Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/). In TCGA cohort, all of the publicly available gastric cancer RNA-Seq data, copy number variation (CNV) data and genomic data information were downloaded from TCGA official website (https://cancergenome.nih.gov/). TCGA RNA-seq data was comprised of 414 tumor samples and 36 non-tumor samples. GSE66229 was comprised of 300 tumor samples and 100 non-tumor samples (details in Tables 1 and 2).

Bioinformatics Analysis for Identifying LAMB1 Expression

Raw CEL files of the micro array of each GEO dataset were normalized by the quantile method of Robust Multichip Analysis (RMA) from the R\textsuperscript{12} affy package and the normalized gene expression levels were presented as log2-transformed values by RMA. The copy number variation (CNV) v3 data of 406 gastric cancer patients (TCGA) were annotated by\textsuperscript{13} annovar. And the absolute value of segment mean >0.3 will be defined as gain or loss.

TICs Profile

CIBERSORTx was used to calculate the absolute score of tumor-infiltrating immune cells (TICs) in gastric tumor tissues, with reference to\textsuperscript{14} LM22 gene signature. The CIBERSORTx is an analytical tool to impute gene expression profiles and provide an estimation of the abundances of member cell types in a mixed cell population, using gene expression data. LM22 defines 22 subtypes of immune cells referring to the annotated gene signature matrix, downloaded from the CIBERSORTx website portal (https://cibersortx.stanford.edu/). The 22 immune cells contain 2 subtypes of B cells, 7 subtypes of T cells, 2 subtypes of NK cells, 3 subtypes of Macrophages, 2 subtypes of Dendritic cells, 2 subtypes of Mast cells, Monocytes, Eosinophils and Neutrophils. Wilcoxon rank-sum test was performed to analyze the differential abundances of infiltrating immune cells between low- and high-LAMB1 level groups, which were visualized using the “ggplot2” package.

Survival Analysis

Patients, defining the median of LAMB1 expression values as the cutoff point, were classified into a low expression group and high expression group to analyze the correlation between LAMB1 expression with survival rates and clinical pathological characteristics. The survivorship curve was plotted by R package\textsuperscript{15,16} survival and r-base.

Identification of LAMB1-Related Genes

The Pearson’s correlation coefficient between the mRNA expression value of LAMB1 and other gene were calculated. If any genes’ absolute value of Pearson’s correlation coefficient > 0.6 and adj. $P$-value < 0.05, it were defined as LAMB1-related genes.

KEGG/GO Biological Process Enrichment

The R package\textsuperscript{17} clusterProfiler was used to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis and Gene Ontology (GO) enrichment analysis, including biological process (BP), cellular components (CC), and molecular function (MF). Adjusted $P$-value < 0.05 was considered as the threshold.
Protein-Protein Interaction (PPI) Network Construction

Protein-protein interaction (PPI) networks were analyzed using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING; http://www.string-db.org/), an online database comprising comprehensive known and predicted interactions, to determine the interactive relationships among the LAMB1-related genes. Then, the PPI pairs were inputted into Cytoscape software version 3.8.0 (http://www.cytoscape.org) to construct the PPI network, and the cytoscape plug-in cytoHuba were used to calculate the top 10 central genes.

Statistical Analyses

All analyses were carried out using the R language, version 3.6.3, and nonparametric rank sum tests and t tests revealed that the LAMB1 mRNA expression differences in different clinical variables were visualized through the ggplot2 package. The Mann-Kendall test were performed to uncover the trend of change by R package trend. Chi-square test or Fisher exact test were used for enumeration data.

Results

LAMB1 Expression and Mutation in Gastric Cancer

As illustrated in Figure 1, the expression of LAMB1 in tumor samples was higher than non-tumor samples in ACRG ($P = 3.2e-10$, Figure 1A). The similar tendency was observed in TCGA cohort ($P = 0.04398065$, Figure 1B). Then we inspected somatic mutation and copy number variation of LAMB1. The TCGA cohort showed more frequent copy number variation compared with somatic mutation.30 patients generated somatic mutation in 406 patients, but most of these mutations belong to synonymous variant or missense variant.64 patients generated copy number variation in 406 patients, include 55 gains and 9 losses, but, in those patients with both mRNA data and CNV data, little correlation is showed ($r = 0.1360588$, $P$-value $= 0.01839$, Figure 1C).

Association Between LAMB1 and Clinicopathological Features in Gastric Cancer Patients

In order to clarify the relationship between LAMB1 mRNA expression and the clinical characteristics of gastric cancer
samples, we respectively divided TCGA and ACRG cohorts into high expression groups and low expression groups based on the median of LAMB1 mRNA expression. As delineated in Tables 1 and 2, both in ACRG and TCGA, age, gender and distant metastasis status were not showing significantly difference between LAMB1 expression low group and high group (P > 0.05). Both in the TCGA and ACRG cohorts, there was a significant increase in T3 and T4 cases in the LAMB1 high expression group (P = 0.0001635 in TCGA and P = 0.003746 in ACRG). The LAMB1 high expression group in the GEO cohort seems to have more N2, N3 cases (P = 0.01652) and more diffuse gastric cancer (P = 0.013), but this was not found in the TCGA cohorts (P > 0.05). Therefore, we investigated the expression of LAMB1 in different gastric cancer subtypes and TNM stages. In the TCGA cohort, the expression of LAMB1 in T2 stage gastric cancer was significantly higher than it in T1 stage and the expression of LAMB1 in T3 stage tumors was significantly higher than it in T2 stage. LAMB1 mRNA expression showed a significant increasing trend with the increase of tumor T stage (P trend < 0.05, Figure 2A), and a

| ACRG | Total | Low (57-70) | High (52-70) | P |
|------|-------|-------------|--------------|----|
| Age  | 64(55-70) | 65(57-70) | 62(52-70) | 12690 | 0.05529 |
| Gender | Female | 101 | 54 | 47 | 0.53734 | 0.4635 |
| Male | 199 | 96 | 103 | 0.1174 | 0.003746 |
| Tstage | T1 | 0 | 0 | 0 | 10.254 | 0.01652 |
| T2 | 188 | 108 | 80 | 0.003746 |
| T3 | 91 | 34 | 57 | 0.01652 |
| T4 | 21 | 8 | 13 | 0.01652 |
| Nstage | N0 | 38 | 21 | 17 | 0.01652 |
| N1 | 131 | 76 | 55 | 0.01652 |
| N2 | 80 | 36 | 44 | 0.01652 |
| N3 | 51 | 17 | 34 | 0.01652 |
| Mstage | M0 | 273 | 138 | 135 | 0.01652 |
| M1 | 27 | 12 | 15 | 0.01652 |

| Subtype | MSI | 68 | 50 | 18 | 37.87 | 3.012e-08 |
| EMT | 46 | 7 | 39 | 0.013 |
| TP53- | 107 | 51 | 56 | 0.013 |
| TP53+ | 79 | 42 | 37 | 0.013 |

| Type | Intestinal type | 146 | 83 | 63 | 8.6851 | 0.013 |
| Diffuse type | 135 | 55 | 80 | 0.013 |
| Mix or other | 19 | 12 | 7 | 0.013 |

Table 2. Patients in ACRG Dataset.

Figure 1. The expression of LAMB1 in gastric cancer. A-B. Comparison of LAMB1 mRNA expression between tumor and normal samples in ACRG (A) and TCGA-STAD (B). C. The relationship between mRNA of LAMB1 and copy number variation of LAMB1 in TCGA-STAD.
similar trend was observed in ACRG (Figure 2D). More patients,
in ACRG, accompanied with lymph node metastasis in the
LAMBI high expression group, but there is no similar situation
in TCGA (Tables 1 and 2). Therefore we separately analyzed the
relationship between the expression of LAMBI and lymph node
metastasis in different datasets. The results, both in ACRG and
TCGA, showed a tendency of LAMBI expression increased
with N stages (Figure 2B, \(P_{\text{trend}} = 0.02739\) in TCGA,
Figure 2E, \(P_{\text{trend}} = 0.00453\) in ACRG). In addition, the expres-
sion of LAMBI in patients with distant metastasis tended to be
higher than that in patients without metastasis, but there was no
significant statistical difference (Figure 2C, \(P = 0.16\) in TCGA,
Figure 2E, \(P = 0.11\) in ACRG), which may be due to lower
proportion of ACRG and TCGA distant metastases. Subse-
quently, we analyzed the LAMBI expression of different sub-
types of gastric cancer, and the results suggested that the
expression of LAMBI in gastric cancer has nothing to do with
the tumor location (\(P > 0.5\), Figure 3A and Figure 3D). The
expression of LAMBI in diffuse gastric cancer in ACRG was
significantly higher than it in intestinal gastric cancer or mixed
gastric cancer (Figure 3E), but there was no significant differ-
ence in the expression of LAMBI in the 3 gastric cancers in the
TCGA cohort (Figure 3B). Finally, we analyzed the expression
of LAMBI in different subtypes in the molecular typing pro-
posed by the TCGA project and the ACRG project. In TCGA,
the expression of microsatellite unstable (MSI) LAMBI was
significantly lower than that of other subtypes (Figure 3C). The
expression of LAMBI of MSI subtype in ACRG was also lower
than that of other subtypes (Figure 3F). At the same time, as the
prognosis of the subtypes deteriorated, the expression of
LAMBI showed obviously increasing trend (\(P_{\text{trend}} < 0.05\),
Figure 3F).

**Associations Between LAMBI and Survival in Gastric Cancer Patients**

Considering that the expression of LAMBI is closely related
to the T staging of gastric cancer and the MSI subtype of
gastric cancer, Kaplan-Meier curves, along with log-rank test,
evaluated the association between LAMBI mRNA and prog-
nosis of patients with gastric cancer. It was found that
increased mRNA expression of LAMBI in gastric tumor tis-
tues was considerably associated with poor overall survival
(Figure 4A and Figure 4B) in patients with gastric cancer.
Then univariate and multivariate Cox proportional hazards
models with age, gender and other factors as covariates were
performed, and the factors with a \(P\) value of less than 0.1 in
the univariate COX proportional hazard model are included in
the multivariate COX proportional hazard model. Regardless
of TCGA or ACRG, the LAMBI expression, just like TNM
stages, has a significant impact on the prognosis of gastric
cancer patients (Table 3).
Correlation of LAMB1 With Immune Signatures in Gastric Cancer Patients

CIBERSORTx algorithm calculated the absolute score of 22 infiltrating immune cells in the gastric cancer samples (Figure 5). Then, Wilcoxon rank-sum test was used to reveal the difference of infiltrating immune cells between the low- and high-LAMB1 expression level samples. Both in the TCGA and ACRG cohorts, high-LAMB1 level group presented a significantly higher infiltration levels of resting CD4\(^+\) memory T cells and M2 macrophages than the low-LAMB1 group (Figure 5). On the other hand, the low-LMB1 level group showed a higher infiltration level of activated NK cells and activated CD4\(^+\) memory T cells in the TCGA cohorts (Figure 5B). And a similar trend was observed in ACRG, although the difference in the trend is not significant (Figure 5A).
KEGG/GO Biological Process Enrichment

The GO analysis of LAMB1-related genes showed that the most of enriched pathways were closely related to extracellular matrix (ECM) and cancer progression, such as extracellular matrix organization, extracellular structure organization, cell-substrate adhesion, Ras protein signal transduction, cell-substrate junction assembly (Figure 6A). The results from KEGG analysis indicated that among the pathways in which these genes were particularly enriched, many were closely related to cancer progression, such as the PI3K-Akt signaling pathway, focal adhesion, and ECM-receptor interaction (Figure 6B).

Protein-Protein Interaction (PPI) Network Construction

Using the STRING online database and Cytoscape software, 36 genes of the 113 LAMB1-related genes were filtered into the PPI network complex, containing 61 edges in their intricate network (Figure 7), and the top 10 central genes, calculated by the cytoscape plug-in cytoHuba, were ITGB1, THBS1, COL4A1, NID1, HSPG2, SPARC, COL4A2, COL1A2, LAMC1 and MMP2.

Discussion

In addition to tumor cells, cancer also includes a complex ecosystem composed of peripheral blood vessels, extracellular matrix (ECM), other non-malignant cells and signaling molecules. These non-tumor cell components together constitute the tumor microenvironment (TME). In recent decades, cancer research has undergone an overturning shift from focusing exclusively on a seemingly obvious target in malignant cells toward appreciation of key roles of the tumor microenvironment (TME) in cancer progression and therapy. The tumor microenvironment (TME), including
laminins, in the tumor microenvironment is important for tumor invasion, progression and chemoresistance. This is further confirmed by numerous advances in tumor microenvironment research. Many subtypes of laminins have been described to promote cell adhesion and migration via ITG interaction. Studies have confirmed that LAMB1 is associated with tumor progression in glioma and breast cancer. In addition, LAMB1, in prostate cancer, participate in cell movement and is involved in tumor invasion into ECM. And study shows that LAMB1 has a crucial role in the invasion and metastasis of human HCC. To gain more detailed insights into the potential functions of LAMB1 in GC and its regulatory network, bioinformatics analysis of public sequencing data was performed.

Figure 6. GO (A) and KEGG (B) biological process enrichment of LAMB1-related genes.

Figure 7. Protein-protein interaction (PPI) network of LAMB1-related genes, the top 10 central genes were marked by red.
More than 600 GC clinical samples including TCGA and ACRG revealed that the mRNA level of LAMB1 in GC was slightly higher than it in normal gastric mucosa (Figure 1). Despite the fact that the increase in the copy number of LAMB1 occurs frequently in gastric cancer tissues, the up-regulation of copy number of LAMB1 has relatively little effect on mRNA levels. It seems to indicate that LAMB1 is more regulated by its related genes. In addition, the high expression of LAMB1 is significantly related to low survival rate and high T stage. The Mann-Kendall test showed that ACRG and TCGA cases shared a significant increasing trend in LAMB1 mRNA expression with the increase of tumor T stage and N stage. Another study in stomach cancer pointed out that LAMB1 can promote tumor growth, cell invasion and migration of gastric cancer cells, which is in good agreement with our results.

Tumor-infiltrating immune cells as integral component of the tumor microenvironment are associated with tumor progression, prognosis and responses to immunotherapy. Therefore, we studied the relationship between LAMB1 and the tumor immune micro-environment of gastric cancer in TCGA and ACRG. The study found that, in tissues with high expression of LAMB1, M2 macrophages and resting CD4\(^+\) memory T cells increased significantly, while the activated CD4\(^+\) memory T cells decreased. Memory B cells, plasma cells and NK activated cells all have a downward trend, although not all of them have significant statistical differences. In gastric cancer, contrary to resting CD4\(^+\) memory T cells and plasma cells, activated CD4\(^+\) memory T cells and plasma cells, has been known as a protective factor. And for macrophages, the 2 main polarization-based subtypes have more or less opposite functions in tumor: M1 macrophages are believed to exert anti-tumor effect by promoting the Th1 immune response; M2 macrophages favor the Th2 immune response, which facilitates tumor progression. This discovery that a high level of LAMB1 expression in gastric cancer predicted an increase in immune cells with a poor prognosis and a decrease in cells with a good prognosis is highly consistent with our previous results. It seems to indicate that LAMB1 may be involved in the activation of CD4\(^+\) memory T cells and the polarization or recruitment of macrophages. After using the COX proportional hazard model to correct the influence of age, gender and other factors, high expression of LAMB1 still predicts a poorer prognosis.

Unfortunately, we have not yet conducted experimental studies to explore the potential mechanism of LAMB1 in the development of gastric cancer. This will be done in our subsequent research. However, combining previous reports and the findings of this study, we can still put forward the conclusion that GC patients with high expression of LAMB1 have a poor prognosis. Moreover, it may be related to microenvironmental changes in tumors.

**Authors’ Note**
All of the authors have read and approved the manuscript. Our study did not require an ethical board approval because it did not contain human or animal trials.

**Acknowledgments**
The authors thank TCGA and ACRG for their contributions to human tumor research and the establishment of open database. The authors also thank Chongqing Health and Family Planning Commission for their financial support.

**Declaration of Conflicting Interests**
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Chongqing Health and Family Planning Commission [Grant Number: 2017ZDXM010].

**ORCID iD**
Tao Ran, MD  
https://orcid.org/0000-0001-5742-745X
References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492

2. Van Cutsem E, Sagar X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet Lond Engl. 2016;388(10060):2654-2664. doi:10.1016/S0140-6736(16)30354-3

3. Hecht JR, Bang Y-J, Qin SK, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC—a randomized phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(5):443-451. doi:10.1200/JCO.2015.62.6598

4. Adelstein DJ, Rodriguez CP, Rybicki LA, Ives DI, Rice TW. A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction. Invest New Drugs. 2012;30(4):1684-1689. doi:10.1007/s10637-011-9736-z

5. Tebbutt NC, Price TJ, Ferraro DA, et al. Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in esophagogastric cancer: ATTAX3 phase II trial. Br J Cancer. 2016;114(5):505-509. doi:10.1038/bjc.2015.440

6. Qin Y, Rodin S, Simonson OE, Hollande F. Laminins and cancer: ATTAX3 phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction. J Cell Biochem. 2016;117(6):57-58:213-243. doi:10.1016/j.matbio.2016.08.007

7. Ramovs V, Te Molder L, Sonnenberg A. The opposing roles of laminin-binding integrins in cancer. Matrix Biol J Int Matrix Biol. 2017;57-58:213-243. doi:10.1016/j.matbio.2016.08.007

8. Xie S, Mo P, Li N, et al. Tumor-infiltrating lymphocyte-based risk score for predicting prognosis in gastric cancer. Cancer Lett. 2017;368(1):7-13. doi:10.1016/j.canlet.2017.02.12

9. Alinezhad S, Väänänen R-M, Mattsson J, et al. Validation of novel biomarkers for prostate cancer progression by the combination of bioinformatics, clinical and functional studies. PloS One. 2016;11(5):e0155901. doi:10.1371/journal.pone.0155901

10. Szelarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(Database issue):D362-D368. doi:10.1093/nar/gkw937

11. Killcoyne S, Carter GW, Smith J, Boyle J. Cytoscape: a community-based framework for network modeling. Methods Mol Biol Clifton NJ. 2009;563:219-239. doi:10.1007/978-1-60761-175-2_12

12. R Core Team. R: A Language and Environment for Statistical Computing. 2020. R Foundation for Statistical Computing. Updated March 10, 2020. Accessed February 29, 2020. URL: https://www.R-project.org/

13. Wickham H. Ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag: 2016.

14. Lee H, Kim W-J, Kang H-G, et al. Upregulation of LAMB1 via ERK/c-Jun axis promotes gastric cancer growth and motility. Int J Mol Sci. 2021;22(2):626. doi:10.3390/ijms22020626

15. Schematic diagram showing high-grade glioma progression through periventricular subventricular zones. J Cell Biochem. 2019;120(3):2756-2765. doi:10.1002/jcb.27646
31. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30(2):193-204. doi:10.1016/j.ctrv.2003.07.007
32. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49(17):4682-4689.
33. Vergadi E, Ieronymaki E, Lyroni K, Vaporidi K, Tsatsanis C. Akt signaling pathway in macrophage activation and M1/M2 polarization. J Immunol Baltim Md 1950. 2017;198(3):1006-1014. doi:10.4049/jimmunol.1601515
34. Marquis M, Boulet S, Mathien S, et al. The non-classical MAP kinase ERK3 controls T cell activation. PloS One. 2014;9(1):e86681. doi:10.1371/journal.pone.0086681
35. Kashihara H, Shimada M, Yoshikawa K, et al. Correlation between thrombospondin-1 expression in non-cancer tissue and gastric carcinogenesis. Anticancer Res. 2017;37(7):3547-3552. doi:10.21873/anticanres.11724
36. Wang H-L, Zhou P-Y, Zhang Y, Liu P. Relationships between abnormal MMP2 expression and prognosis in gastric cancer: a meta-analysis of cohort studies. Cancer Biother Radiopharm. 2014;29(4):166-172. doi:10.1089/cbr.2014.1608
37. Li Z, Li A-D, Xu L, et al. SPARC expression in gastric cancer predicts poor prognosis: results from a clinical cohort, pooled analysis and GSEA assay. Oncotarget. 2016;7(43):70211-70222. doi:10.18632/oncotarget.12191
38. Xu S, Xu H, Wang W, et al. The role of collagen in cancer: from bench to bedside. J Transl Med. 2019;17(1):309. doi:10.1186/s12967-019-2058-1